Beyond Creatinine — Next-Generation Nephrotoxicity Biomarkers

In 2008, the Predictive Safety Testing Consortium (PSTC), led by the FDA's Critical Path Institute (C-Path), submitted qualification data to the FDA and EMA for a panel of urinary kidney injury biomarkers. Both agencies subsequently issued guidance accepting KIM-1, Clusterin, NGAL, Osteopontin, Albumin, β2-Microglobulin, and Cystatin C as biomarkers of drug-induced kidney injury in preclinical safety studies — enabling their inclusion alongside traditional histopathology and clinical chemistry in IND-enabling toxicology programs. This regulatory recognition transformed kidney safety assessment: for the first time, molecular biomarkers could complement (or in some cases precede) the histopathological reference standard, providing quantitative, temporal, and reversible-readout data that terminal histopathology cannot provide.

Kidney Injury Biomarkers — Site-Specific Detection & Regulatory Status

  • KIM-1/HAVCR1 (Proximal Tubule): the most specific proximal tubular injury marker. Transmembrane glycoprotein upregulated on apical membrane of injured proximal epithelial cells within hours of toxic or ischemic insult. FDA/EMA-recognized for preclinical rat nephrotoxicity. Measured in both our Human 7-Plex and Rat 4-Plex.
  • NGAL/LCN2 (Proximal Tubule): the most sensitive AKI marker — elevated in urine within 2–6 hours across multiple etiologies (ischemic, toxic, septic). FDA/EMA-recognized. Measured in Human 6-Plex and Rat 4-Plex. Also measurable in plasma for systemic vs. renal source discrimination.
  • Clusterin (Proximal & Distal Tubule): pro-survival glycoprotein upregulated during tubular regeneration. FDA/EMA-recognized. More sensitive and specific than serum creatinine or BUN for detecting drug-induced tubular damage. Measured in both Human panels.
  • Cystatin C (Glomerular): freely filtered cysteine protease inhibitor — urinary elevation indicates impaired proximal tubular reabsorption. Independent of muscle mass, unlike creatinine. FDA/EMA-recognized.
  • Osteoactivin/GPNMB (Proximal Tubule): lysosomal protein induced by proximal tubular stress. FDA/EMA-recognized for preclinical rat studies.
  • Calbindin & TFF3 (Distal Tubule/Collecting Duct): Calbindin is a calcium-binding protein decreased in distal tubular injury. TFF3 is a mucosal protective factor decreased in collecting duct injury. Both provide site-specific distal nephron assessment not available from standard markers.